A phase II study of nab-PTX in combination with RAM in patients with pre-treated AGC: results of final analysisdoi:10.1093/annonc/mdy375.005Takashima, AtsuoBando, HideakiShimodaira, HidekiFujitani, KazumasaYamaguchi, KenseiNakayama, Norisuke
Background Ramcirumab (RAM) plus paclitaxel (PTX) is the standard second-line chemotherapy for metastatic gastric cancer. The ABSOLUTE trial showed that weekly nanoparticle albumin-bound (nab)-PTX was non-inferior to weekly PTX in terms of overall survival (OS). [Objective] This study aimed ...
The PFS was 5.7 months in the nab-PTX plus RAM group and 5.1 months in the PTX plus RAM group (p = 0.12). OS was not reached in the nab-PTX plus RAM group and was 8.6 months in the PTX plus RAM group (p = 0.27). The improvement rate of ascites did not differ ...